Pentagon to compensate firefighters sickened by forever chemicals
H.R. 705 — To direct the Secretary of Defense to establish a compensation fund for military firefighters exposed to PFAS. · Filed by Marilyn Strickland (D-WA) · 3 cosponsors · Introduced Jan 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Defense to establish a compensation fund within two years to pay military firefighters and their survivors who became ill from exposure to PFAS (per- and polyfluoroalkyl substances, commonly called 'forever chemicals') during their service. Eligible firefighters receive medical benefits, transportation costs, and disability or death compensation, with payments going to spouses, children, parents, or other relatives depending on family circumstances.
Why we flagged it
The bill's core function is establishing a dedicated compensation and medical-benefits program for a specific occupational group (military firefighters) harmed by exposure to a known hazardous substance during government service. This is a targeted public-health and worker-protection measure, not a broad appropriation or regulatory change.
What the text implies
- The bill presumes PFAS exposure at military installations without requiring individual proof, shifting the evidentiary burden to the government—a significant procedural advantage for claimants that may accelerate payouts but could also create administrative complexity in determining facility-specific exposure periods.
- By covering both current and former firefighters and their survivors, the bill creates a potentially long-tail liability for the DoD, as PFAS-related illnesses may manifest years or decades after exposure, requiring sustained funding and claims administration.
The full analysis lists 3 implications of this text.
Who stands to gain
Military firefighters and their families (primary beneficiaries—not a financial sector); Medical service providers and pharmaceutical companies supplying treatments to eligible beneficiarie